Tue, Jul 22, 2014, 9:43 AM EDT - U.S. Markets close in 6 hrs 17 mins

Recent

% | $
Click the to save as a favorite.

Advaxis, Inc. Message Board

jckrdu 16 posts  |  Last Activity: Jul 9, 2014 8:22 AM Member since: Feb 27, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Anyone know the time of today's meeting? Thanks in advance.

    Sentiment: Strong Buy

  • Reply to

    BIO Int'l PR

    by donjayouworry Jun 12, 2014 7:43 AM
    jckrdu jckrdu Jun 12, 2014 8:05 AM Flag

    Agree. The below statement seems like a change in direction from what we were told during the conference call. During the cc, I thought I heard that they planned to execute Phase 1 for prostate and breast themselves. The below sounds completely different.... and a better approach IMO.
    _____________________________

    "With our early stage assets, ADXS-PSA and ADXS-cHER2, we will be seeking partners that would be willing to co-develop these assets to confirm the safety profile and detect meaningful efficacy signals in an early stage trial."

    Sentiment: Strong Buy

  • Reply to

    Efficacy

    by nkl0145 Jun 4, 2014 3:49 PM
    jckrdu jckrdu Jun 5, 2014 11:56 AM Flag

    Last gap in ATHX chart between $1.59 and $1.60 just filled.

    Sentiment: Strong Buy

  • Reply to

    VOTE

    by pcdoctor1_1999 Jun 4, 2014 5:30 PM
    jckrdu jckrdu Jun 4, 2014 9:37 PM Flag

    Watch the gaps... $2.80 - $2.85 and $3.05 - $3.20. maybe these latest gaps won't fill, but over the years, the others have.

    Sentiment: Buy

  • Reply to

    Moore Study two year results

    by williamjay63 May 31, 2014 10:53 AM
    jckrdu jckrdu May 31, 2014 2:28 PM Flag

    Agree James. Why would any patient or doctor choose or prescribe chemo when ADXS becomes available? (Note - 18% 24 month survival... just wanted to correct my prior post.)

    Sentiment: Strong Buy

  • Reply to

    Moore Study two year results

    by williamjay63 May 31, 2014 10:53 AM
    jckrdu jckrdu May 31, 2014 2:16 PM Flag

    So ADXS got better 24 month results (19% survival) without all the negative side effects of chemo. Sounds like a no-brainer if I were a patient..

    Sentiment: Strong Buy

  • Chart looking decent. Support building at around $1.50 for next leg up.

    Sentiment: Strong Buy

  • jckrdu jckrdu May 20, 2014 6:18 PM Flag

    You should send that post to the company. It says it all.

    Sentiment: Hold

  • Reply to

    new proxy

    by ac158305 May 20, 2014 7:41 AM
    jckrdu jckrdu May 20, 2014 8:54 AM Flag

    Agree. Not many changes at all... except for a long explanation justifying why the incentive shares are needed. In Dan's letter to shareholders, it was interesting to see him characterize the last capital raise at $3 as a success. Some thoughts...
    _____________________
    IMO, shareholders won't be happy as the only changes are that they reduced the number of management incentive shares they're requesting from 2 million to 1.6 million, and the x-CEO (Tom Moore) will no longer have a seat on the Board. IMO, shareholders were expecting more significant changes to better align management interests with shareholder interests, and IMO this new proxy falls short. The proxy includes detailed justifications for why the incentive shares are needed from managements perspective. With the last stock offering done at $3.00 and ADXS trading 10% below that level, I don't see how the request for 1.6 million incentive shares will pass.... and may generate a negative reaction from shareholders. This new proxy is not going to generate more interest in the stock.

    Some slightly positive news is that they expect their partner (Aratana) to commercialize the first pet therapy by the end of 2015. That's 1.5 years away which is relatively soon, but I doubt the market will price any of that in at this time.

    Sentiment: Hold

  • Reply to

    ASCO

    by kwallis95 May 13, 2014 6:59 PM
    jckrdu jckrdu May 14, 2014 10:48 PM Flag

    Excerpt from GOG abstract below. Looks like enrollment is going to take awhile...
    _______________

    This protocol is a 2-stage design with 12-month survival as the primary endpoint and with a planned sample size of up to 67 patients. Patients will receive ADXS11-001 at a dose of 1x109 CFU on Day 1 and repeat every 28 days for 3 total doses in the absence of disease progression or unacceptable toxicity, with each dose followed at 72 hours by a 7 day course of ampicillin, 500 mg QID. Tumor tissue and serum samples may be collected periodically for translational research. After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years. As of January 31, 2014, enrollment has been completed in the 9 patient safety lead-in portion of the study and enrollment continues. Clinical trial information: NCT01266460.

    Sentiment: Strong Buy

  • Reply to

    ASCO

    by kwallis95 May 13, 2014 6:59 PM
    jckrdu jckrdu May 14, 2014 6:33 PM Flag

    There was also a statement at the very end of the abstract that said they have information on subgroups, or words to that effect. That data could be helpful when designing entry criteria for Phase 3.

    Sentiment: Strong Buy

  • Reply to

    stroke results

    by translationhell May 13, 2014 4:04 PM
    jckrdu jckrdu May 13, 2014 5:13 PM Flag

    In the conference call, Gil guided that "topline results" for stroke would be announced by end of year.

    Sentiment: Strong Buy

  • Reply to

    ATHX and Japan

    by nkl0145 May 13, 2014 9:22 AM
    jckrdu jckrdu May 13, 2014 10:05 AM Flag

    Agree. IMO, the gameplan is to close the partnering deal for Multistem for stroke in Japan before the US stroke results are out. There's enough data out for Gil and the Japanese partner to structure a win-win partnership with some upfront cash and milestone payments, so Athx and the Japanese partner get going and start working together on the trial design in Japan now. IMO, news of deal for stroke in Japan could happen at any time.

    Sentiment: Strong Buy

  • jckrdu jckrdu May 5, 2014 12:09 PM Flag

    Nice post. Newby here still doing some DD... how confident are you that stroke results will show efficacy?

    Sentiment: Buy

  • Saw the below dated yesterday, 5/3.
    _______________________________________
    Healthcare Gainers: Athersys (NASDAQ:ATHX), Acadia Healthcare Company (NASDAQ:ACHC), Aastrom Biosciences (NASDAQ:ASTM), Biostar Pharmaceuticals (NASDAQ:BSPM)
    Posted by Carmen Gutierrez on May 03, 2014 First Analysis assumed coverage on shares of Athersys Inc (NASDAQ:ATHX) in a report issued. The firm issued an overweight rating and a $5.00 target price on the stock. Athersys, Inc. (NASDAQ:ATHX) stock opened at $1.44 in last session, and closed at $1.63, while the day range of ATHX stock is $1.40 – $1.67. The stock showed a negative weekly performance of -40.29%

    Sentiment: Strong Buy

  • Reply to

    Trading for the stock..

    by b.ostrov Apr 25, 2014 11:08 AM
    jckrdu jckrdu Apr 25, 2014 7:07 PM Flag

    Agree. I don't think the new shareholders that recently bought at $3 and are now down 10% will be lining up to vote yes to that proxy.

    Sentiment: Strong Buy

ADXS
2.9643+0.2642(+9.78%)9:41 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.